UV-based therapy

Dermatologic Clinics

Volumn 32, Issue 3, 2014, Pages 399-413

  Totonchy, Mariam B ^a   Chiu, Melvin W ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Excimer; Narrowband UVB; Phototherapy; Psoralen; Psoriasis; PUVA; UV therapy; UV A1

Indexed keywords

PSORALEN; PHOTOSENSITIZING AGENT;

BROADBAND ULTRAVIOLET B PHOTOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; EXCIMER LASER; HUMAN; IATROGENIC DISEASE; NARROWBAND ULTRAVIOLET B PHOTOTHERAPY; OUTCOME ASSESSMENT; PHOTOTHERAPY; PRIORITY JOURNAL; PSORALEN AND ULTRAVIOLET A PHOTOTHERAPY; PSORIASIS; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIATION INJURY; RADIATION RESPONSE; REVIEW; SKIN DISEASE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ULTRAVIOLET A 1PHOTOTHERAPY; ULTRAVIOLET B RADIATION; PHOTOCHEMOTHERAPY; PROCEDURES; SKIN DISEASES; ULTRAVIOLET PHOTOTHERAPY;

HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN DISEASES; ULTRAVIOLET THERAPY;

EID: 84901682940     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2014.03.003     Document Type: Review

References (135)

1. Fitzpatrick T.B., Pathak M.A. Historical aspects of methoxsalen and other furocoumarins. J Invest Dermatol 1959, 32(2 Pt 2):229-231.
2. Pathak M.A., Fitzpatrick T.B. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. J Photochem Photobiol B 1992, 14(1-2):3-22.
3. Fahmy I.R., Abu-Shady H. Ammi majus Linn.; pharmacognostical study and isolation of a crystalline constituent, ammoidin. Q J Pharm Pharmacol 1947, 20(3):281-291. [discussion: 426].
4. Fahmy I.R., Abu-Shady H. The isolation and properties of ammoidin, ammidin and majudin, and their effect in the treatment of leukodermia. Q J Pharm Pharmacol 1948, 21(4):499-503.
5. Fahmy I.R., Abushady H., Schonberg A., et al. A crystalline principle from Ammi majus L. Nature 1947, 160(4066):468.
6. Roelandts R. The history of phototherapy: something new under the sun?. J Am Acad Dermatol 2002, 46(6):926-930.
7. Parrish J.A., Fitzpatrick T.B., Tanenbaum L., et al. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974, 291(23):1207-1211.
8. Goeckerman W.H. Treatment of psoriasis. Northwest Med 1925, 24:229-231.
9. Ingram J.T. The approach to psoriasis. Br Med J 1953, 12(2):591-594.
10. Wiskemann A. UVB-Phototherapie der Psoriasis mit einer fur die PUVA-Therapie entwickelten Stehbox. Z Hautkr 1978, 53(18):633-636. [in German].
11. Gilchrest B.A., Rowe J.W., Brown R.S., et al. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979, 91(1):17-21.
12. Alsins J., Claesson S., Fischer T., et al. Development of high intensity narrow-band lamps and studies of the irradiation effect on human skin. Irradiation with high intensity lamps. Acta Derm Venereol 1975, 55(4):261-271.
13. Fischer T., Alsins J., Berne B. Ultraviolet-action spectrum and evaluation of ultraviolet lamps for psoriasis healing. Int J Dermatol 1984, 23(10):633-637.
14. Parrish J.A., Jaenicke K.F. Action spectrum for phototherapy of psoriasis. J Invest Dermatol 1981, 76(5):359-362.
15. van Weelden H., De La Faille H.B., Young E., et al. A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988, 119(1):11-19.
16. Green C., Ferguson J., Lakshmipathi T., et al. 311 nm UVB phototherapy-an effective treatment for psoriasis. Br J Dermatol 1988, 119(6):691-696.
17. Krutmann J., Czech W., Diepgen T., et al. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992, 26(2 Pt 1):225-230.
18. Kroft E.B., Berkhof N.J., van de Kerkhof P.C., et al. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol 2008, 59(6):1017-1030.
19. Schlaak J.F., Buslau M., Jochum W., et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994, 102(2):145-149.
20. Uyemura K., Yamamura M., Fivenson D.F., et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 1993, 101(5):701-705.
21. Enk C.D., Sredni D., Blauvelt A., et al. Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. J Immunol 1995, 154(9):4851-4856.
22. Skov L., Hansen H., Allen M., et al. Contrasting effects of ultraviolet A1 and ultraviolet B exposure on the induction of tumour necrosis factor-alpha in human skin. Br J Dermatol 1998, 138(2):216-220.
23. Johnson-Huang L.M., Suarez-Farinas M., Sullivan-Whalen M., et al. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 2010, 130(11):2654-2663.
24. Piskin G., Tursen U., Sylva-Steenland R.M., et al. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers - IL-12, IL-18 and IL-23. Exp Dermatol 2004, 13(12):764-772.
25. Racz E., Prens E.P., Kurek D., et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol 2011, 131(7):1547-1558.
26. Walters I.B., Ozawa M., Cardinale I., et al. Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: differential regulation of cytokines at the single-cell level. Arch Dermatol 2003, 139(2):155-161.
27. Duthie M.S., Kimber I., Norval M. The effects of ultraviolet radiation on the human immune system. Br J Dermatol 1999, 140(6):995-1009.
28. Kammeyer A., Teunissen M.B., Pavel S., et al. Photoisomerization spectrum of urocanic acid in human skin and in vitro: effects of simulated solar and artificial ultraviolet radiation. Br J Dermatol 1995, 132(6):884-891.
29. Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol 2003, 49(Suppl 2):S78-S86.
30. Krueger J.G., Wolfe J.T., Nabeya R.T., et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995, 182(6):2057-2068.
31. Ozawa M., Ferenczi K., Kikuchi T., et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999, 189(4):711-718.
32. Weatherhead S.C., Farr P.M., Jamieson D., et al. Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation. J Invest Dermatol 2011, 131(9):1916-1926.
33. Kolgen W., Both H., van Weelden H., et al. Epidermal Langerhans cell depletion after artificial ultraviolet B irradiation of human skin in vivo: apoptosis versus migration. J Invest Dermatol 2002, 118(5):812-817.
34. McLoone P., Woods G.M., Norval M. Decrease in Langerhans cells and increase in lymph node dendritic cells following chronic exposure of mice to suberythemal doses of solar simulated radiation. Photochem Photobiol 2005, 81(5):1168-1173.
35. Wong T., Hsu L., Liao W. Phototherapy in psoriasis: a review of mechanisms of action. J Cutan Med Surg 2013, 17(1):6-12.
36. van Praag M.C., Mulder A.A., Claas F.H., et al. Long-term ultraviolet B-induced impairment of Langerhans cell function: an immunoelectron microscopic study. Clin Exp Immunol 1994, 95(1):73-77.
37. DeSilva B., McKenzie R.C., Hunter J.A., et al. Local effects of TL01 phototherapy in psoriasis. Photodermatol Photoimmunol Photomed 2008, 24(5):268-269.
38. Seite S., Zucchi H., Moyal D., et al. Alterations in human epidermal Langerhans cells by ultraviolet radiation: quantitative and morphological study. Br J Dermatol 2003, 148(2):291-299.
39. Mork N.J., Austad J. Short-wave ultraviolet light (UVB) treatment of allergic contact dermatitis of the hands. Acta Derm Venereol 1983, 63(1):87-89.
40. Sjovall P., Christensen O.B. Local and systemic effect of ultraviolet irradiation (UVB and UVA) on human allergic contact dermatitis. Acta Derm Venereol 1986, 66(4):290-294.
41. Yoshikawa T., Rae V., Bruins-Slot W., et al. Susceptibility to effects of UVB radiation on induction of contact hypersensitivity as a risk factor for skin cancer in humans. J Invest Dermatol 1990, 95(5):530-536.
42. Miyauchi H., Horio T. Ultraviolet B-induced local immunosuppression of contact hypersensitivity is modulated by ultraviolet irradiation and hapten application. J Invest Dermatol 1995, 104(3):364-369.
43. Skov L., Hansen H., Dittmar H.C., et al. Susceptibility to effects of UVB irradiation on induction of contact sensitivity, relevance of number and function of Langerhans cells and epidermal macrophages. Photochem Photobiol 1998, 67(6):714-719.
44. Soyland E., Heier I., Rodriguez-Gallego C., et al. Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis. Br J Dermatol 2011, 164(2):344-355.
45. Novak Z., Bonis B., Baltas E., et al. Xenon chloride ultraviolet B laser is more effective in treating psoriasis and in inducing T cell apoptosis than narrow-band ultraviolet B. J Photochem Photobiol B 2002, 67(1):32-38.
46. Adrian R.M., Parrish J.A., Momtaz T.K., et al. Outpatient phototherapy for psoriasis. Arch Dermatol 1981, 117(10):623-626.
47. Larko O., Swanbeck G. Home solarium treatment of psoriasis. Br J Dermatol 1979, 101(1):13-16.
48. Walters I.B., Burack L.H., Coven T.R., et al. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999, 40(6 Pt 1):893-900.
49. Almutawa F., Alnomair N., Wang Y., et al. Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol 2013, 14(2):87-109.
50. Picot E., Meunier L., Picot-Debeze M.C., et al. Treatment of psoriasis with a 311-nm UVB lamp. Br J Dermatol 1992, 127(5):509-512.
51. Storbeck K., Holzle E., Schurer N., et al. Narrow-band UVB (311 nm) versus conventional broadband UVB with and without dithranol in phototherapy for psoriasis. J Am Acad Dermatol 1993, 28(2 Pt 1):227-231.
52. Dawe R.S., Cameron H., Yule S., et al. A randomized controlled trial of narrowband ultraviolet B vs bath-psoralen plus ultraviolet A photochemotherapy for psoriasis. Br J Dermatol 2003, 148(6):1194-1204.
53. Schindl A., Klosner G., Honigsmann H., et al. Flow cytometric quantification of UV-induced cell death in a human squamous cell carcinoma-derived cell line: dose and kinetic studies. J Photochem Photobiol B 1998, 44(2):97-106.
54. Menter A., Korman N.J., Elmets C.A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010, 62(1):114-135.
55. Berneburg M., Rocken M., Benedix F. Phototherapy with narrowband vs broadband UVB. Acta Derm Venereol 2005, 85(2):98-108.
56. Guckian M., Jones C.D., Vestey J.P., et al. Immunomodulation at the initiation of phototherapy and photochemotherapy. Photodermatol Photoimmunol Photomed 1995, 11(4):163-169.
57. Hofer A., Hassan A.S., Legat F.J., et al. Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. Br J Dermatol 2005, 152(5):981-985.
58. Hofer A., Hassan A.S., Legat F.J., et al. The efficacy of excimer laser (308 nm) for vitiligo at different body sites. J Eur Acad Dermatol Venereol 2006, 20(5):558-564.
59. Cameron H., Dawe R.S., Yule S., et al. A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol 2002, 147(5):973-978.
60. Dawe R.S., Wainwright N.J., Cameron H., et al. Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment?. Br J Dermatol 1998, 138(5):833-839.
61. Wainwright N.J., Dawe R.S., Ferguson J. Narrowband ultraviolet B (TL-01) phototherapy for psoriasis: which incremental regimen?. Br J Dermatol 1998, 139(3):410-414.
62. Youssef R.M., Mahgoub D., Mashaly H.M., et al. Different narrowband UVB dosage regimens in dark skinned psoriatics: a preliminary study. Photodermatol Photoimmunol Photomed 2008, 24(5):256-259.
63. Kleinpenning M.M., Smits T., Boezeman J., et al. Narrowband ultraviolet B therapy in psoriasis: randomized double-blind comparison of high-dose and low-dose irradiation regimens. Br J Dermatol 2009, 161(6):1351-1356.
64. Schneider L.A., Hinrichs R., Scharffetter-Kochanek K. Phototherapy and photochemotherapy. Clin Dermatol 2008, 26(5):464-476.
65. Boztepe G., Akinci H., Sahin S., et al. In search of an optimum dose escalation for narrowband UVB phototherapy: is it time to quit 20% increments?. J Am Acad Dermatol 2006, 55(2):269-271.
66. Stern R.S., Armstrong R.B., Anderson T.F., et al. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study. J Am Acad Dermatol 1986, 15(3):546-552.
67. Boztepe G., Karaduman A., Sahin S., et al. The effect of maintenance narrow-band ultraviolet B therapy on the duration of remission for psoriasis: a prospective randomized clinical trial. Int J Dermatol 2006, 45(3):245-250.
68. Walker D., Jacobe H. Phototherapy in the age of biologics. Semin Cutan Med Surg 2011, 30(4):190-198.
69. Mudigonda T., Dabade T.S., Feldman S.R. A review of targeted ultraviolet B phototherapy for psoriasis. J Am Acad Dermatol 2012, 66(4):664-672.
70. Housman T.S., Pearce D.J., Feldman S.R. A maintenance protocol for psoriasis plaques cleared by the 308 nm excimer laser. J Dermatolog Treat 2004, 15(2):94-97.
71. Lapolla W., Yentzer B.A., Bagel J., et al. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol 2011, 64(5):936-949.
72. Gordon P.M., Diffey B.L., Matthews J.N., et al. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999, 41(5 Pt 1):728-732.
73. Henseler T., Wolff K., Honigsmann H., et al. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet 1981, 1(8225):853-857.
74. Markham T., Rogers S., Collins P., et al. (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003, 139(3):325-328.
75. Melski J.W., Tanenbaum L., Parrish J.A., et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977, 68(6):328-335.
76. Yones S.S., Palmer R.A., Garibaldinos T.T., et al. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006, 142(7):836-842.
77. Bonis B., Kemeny L., Dobozy A., et al. 308 nm UVB excimer laser for psoriasis. Lancet 1997, 350(9090):1522.
78. Feldman S.R., Mellen B.G., Housman T.S., et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 2002, 46(6):900-906.
79. Trehan M., Taylor C.R. Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol 2002, 47(5):701-708.
80. Lavker R.M., Gerberick G.F., Veres D., et al. Cumulative effects from repeated exposures to suberythemal doses of UVB and UVA in human skin. J Am Acad Dermatol 1995, 32(1):53-62.
81. Prystowsky J.H., Keen M.S., Rabinowitz A.D., et al. Present status of eyelid phototherapy. Clinical efficacy and transmittance of ultraviolet and visible radiation through human eyelids. J Am Acad Dermatol 1992, 26(4):607-613.
82. George S.A., Ferguson J. Lesional blistering following narrow-band (TL-01) UVB phototherapy for psoriasis: a report of four cases. Br J Dermatol 1992, 127(4):445-446.
83. Lee E., Koo J., Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 2005, 44(5):355-360.
84. Stern R.S., Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 1994, 73(11):2759-2764.
85. Hearn R.M., Kerr A.C., Rahim K.F., et al. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008, 159(4):931-935.
86. Man I., Crombie I.K., Dawe R.S., et al. The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol 2005, 152(4):755-757.
87. Tauscher A.E., Fleischer A.B., Phelps K.C., et al. Psoriasis and pregnancy. J Cutan Med Surg 2002, 6(6):561-570.
88. Vun Y.Y., Jones B., Al-Mudhaffer M., et al. Generalized pustular psoriasis of pregnancy treated with narrowband UVB and topical steroids. J Am Acad Dermatol 2006, 54(Suppl 2):S28-S30.
89. Coven T.R., Walters I.B., Cardinale I., et al. PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis. Photodermatol Photoimmunol Photomed 1999, 15(1):22-27.
90. Esaki K., Mizuno N. Effect of psoralen + ultraviolet-A on the chemotactic activity of polymorphonuclear neutrophils towards anaphylatoxin C5a des Arg. Photochem Photobiol 1992, 55(5):783-788.
91. Ravic-Nikolic A., Radosavljevic G., Jovanovic I., et al. Systemic photochemotherapy decreases the expression of IFN-gamma, IL-12p40 and IL-23p19 in psoriatic plaques. Eur J Dermatol 2011, 21(1):53-57.
92. Singh T.P., Schon M.P., Wallbrecht K., et al. 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010, 184(12):7257-7267.
93. Coimbra S., Oliveira H., Reis F., et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol 2010, 163(6):1282-1290.
94. Rotsztejn H., Zalewska A., Trznadel-Budzko E., et al. Influence of systemic photochemotherapy on regulatory T cells and selected cytokine production in psoriatic patients: a pilot study. Med Sci Monit 2005, 11(12):CR594-CR598.
95. Godar D.E. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol 1999, 112(1):3-12.
96. Szegedi A., Simics E., Aleksza M., et al. Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44(7):925-931.
97. Krutmann J., Grewe M. Involvement of cytokines, DNA damage, and reactive oxygen intermediates in ultraviolet radiation-induced modulation of intercellular adhesion molecule-1 expression. J Invest Dermatol 1995, 105(Suppl 1):67S-70S.
98. Gruss C., Reed J.A., Altmeyer P., et al. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997, 350(9087):1295-1296.
99. Ju M., Chen K., Chang B., et al. UVA1 irradiation inhibits fibroblast proliferation and alleviates pathological changes of scleroderma in a mouse model. J Biomed Res 2012, 26(2):135-142.
100. Kreuter A., Hyun J., Skrygan M., et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol 2006, 155(3):600-607.
101. Spuls P.I., Witkamp L., Bossuyt P.M., et al. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997, 137(6):943-949.
102. Garbis H., Elefant E., Bertolotti E., et al. Pregnancy outcome after periconceptional and first-trimester exposure to methoxsalen photochemotherapy. Arch Dermatol 1995, 131(4):492-493.
103. Gunnarskog J.G., Kallen A.J., Lindelof B.G., et al. Psoralen photochemotherapy (PUVA) and pregnancy. Arch Dermatol 1993, 129(3):320-323.
104. Stern R.S., Lange R. Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol 1991, 127(3):347-350.
105. Marqueling A.L., Cordoro K.M. Systemic treatments for severe pediatric psoriasis: a practical approach. Dermatol Clin 2013, 31(2):267-288.
106. Krutmann J., Schopf E. High-dose-UVA1 phototherapy: a novel and highly effective approach for the treatment of acute exacerbation of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992, 176:120-122.
107. Berneburg M., Herzinger T., Rampf J., et al. Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study. Br J Dermatol 2013, 169(3):704-708.
108. Salem S.A., Barakat M.A., Morcos C.M. Bath psoralen + ultraviolet A photochemotherapy vs. narrow band-ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T-helper and T-suppressor/cytotoxic cells. Photodermatol Photoimmunol Photomed 2010, 26(5):235-242.
109. Halpern S.M., Anstey A.V., Dawe R.S., et al. Guidelines for topical PUVA: a report of a workshop of the British photodermatology group. Br J Dermatol 2000, 142(1):22-31.
110. Tsui C.L., Levitt J. Practical pearls in phototherapy. Int J Dermatol 2013, 52(11):1395-1397.
111. Gambichler T., Terras S., Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies. Clin Dermatol 2013, 31(4):438-454.
112. Stern R.S., Kleinerman R.A., Parrish J.A., et al. Phototoxic reactions to photoactive drugs in patients treated with PUVA. Arch Dermatol 1980, 116(11):1269-1271.
113. Malanos D., Stern R.S. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol 2007, 57(2):231-237.
114. Chuang T.Y., Heinrich L.A., Schultz M.D., et al. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 1992, 26(2 Pt 1):173-177.
115. Lindelof B., Sigurgeirsson B., Tegner E., et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991, 338(8759):91-93.
116. Stern R.S., Laird N., Melski J., et al. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984, 310(18):1156-1161.
117. Stern R.S., Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988, 91(2):120-124.
118. Stern R.S., Liebman E.J., Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998, 90(17):1278-1284.
119. Stern R.S., Lunder E.J. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998, 134(12):1582-1585.
120. Stern R.S., Thibodeau L.A., Kleinerman R.A., et al. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med 1979, 300(15):809-813.
121. Nijsten T.E., Stern R.S. The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 2003, 121(2):252-258.
122. Murase J.E., Lee E.E., Koo J. Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. Int J Dermatol 2005, 44(12):1016-1021.
123. Stern R.S. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. N Engl J Med 1990, 322(16):1093-1097.
124. Hannuksela A., Pukkala E., Hannuksela M., et al. Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. J Am Acad Dermatol 1996, 35(5 Pt 1):685-689.
125. Hannuksela-Svahn A., Sigurgeirsson B., Pukkala E., et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999, 141(3):497-501.
126. Stern R.S., Nichols K.T., Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997, 336(15):1041-1045.
127. Stern R.S., PUVA Follow up Study The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001, 44(5):755-761.
128. Forman A.B., Roenigk H.H., Caro W.A., et al. Long-term follow-up of skin cancer in the PUVA-48 cooperative study. Arch Dermatol 1989, 125(4):515-519.
129. Lindelof B. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?. Drug Saf 1999, 20(4):289-297.
130. Morison W.L., Baughman R.D., Day R.M., et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998, 134(5):595-598.
131. Lindelof B., Sigurgeirsson B., Tegner E., et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999, 141(1):108-112.
132. Gambichler T., Othlinghaus N., Tomi N.S., et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009, 160(3):652-658.
133. Kroft E.B., van de Kerkhof P.C., Gerritsen M.J., et al. Period of remission after treatment with UVA-1 in sclerodermic skin diseases. J Eur Acad Dermatol Venereol 2008, 22(7):839-844.
134. Calzavara-Pinton P., Monari P., Manganoni A.M., et al. Merkel cell carcinoma arising in immunosuppressed patients treated with high-dose ultraviolet A1 (320-400 nm) phototherapy: a report of two cases. Photodermatol Photoimmunol Photomed 2010, 26(5):263-265.
135. Wallenfang K., Stadler R. Assoziation zwischen UVA1 bzw. Bade-PUVA-Bestrahlung und Melanomentwicklung?. Hautarzt 2001, 52(8):705-707. [in German].